I-Mab Strengthens Leadership with Key Appointments
ROCKVILLE, Md. — In a strategic move to enhance its governance and operational capabilities, I-Mab (NASDAQ: IMAB), a global biotech company dedicated to precision immuno-oncology, has announced significant changes in its Board of Directors and the formation of a new Research and Development Committee (R&D Committee). This development is seen as a pivotal moment for the Company as it aligns its leadership for future growth and innovation.
New Additions to the Board of Directors
The Company is pleased to welcome Dr. Robert Lenz and Ms. Xin Liu as the newest independent directors on its Board. Their appointments are effective immediately, while Dr. Sean Cao’s ongoing contributions, appointed as of May, will continue to guide the Company.
Dr. Robert Lenz brings a wealth of experience from his previous role as the Executive Vice President and Head of Research and Development at Neumora Therapeutics. He is widely recognized for overseeing the development of several medicines through regulatory approval, demonstrating his deep expertise in the biotech sphere. Dr. Lenz holds both an MD and PhD from the University of Maryland School of Medicine, alongside a history of leadership roles at Amgen and Abbott Laboratories.
Ms. Xin Liu's Financial Expertise
Ms. Xin Liu, currently the Investment Director at Hony Capital’s Healthcare Group, is noted for her comprehensive background in finance. Her prior experience as Vice President of Investments at CCBPE and as Investment Manager at the Fosun Group lends robust expertise to the Board. Liu's academic background includes engineering and finance degrees from prestigious institutions like MIT and Washington University in St. Louis, positioning her to make significant contributions to the Company's financial strategies.
Introducing the R&D Committee
To further amplify I-Mab's commitment to scientific innovation, the newly established R&D Committee will be chaired by Dr. Robert Lenz. This Committee is designed to foster a culture of rigorous research and strategic foresight, ensuring that the Company remains at the forefront of immuno-oncology advancements.
Contributions from Dr. Sean Cao
Dr. Sean Cao, also an esteemed addition to the Board, is currently an Operating Partner at CBC Group and has been instrumental in founding several biotech firms. His diverse background spans leadership positions across corporations, including Sanofi and Johnson & Johnson, along with a strong academic foundation capped by an MBA from the Wharton School of the University of Pennsylvania.
Expanding the Scientific Advisory Board
Additionally, the Company has expanded its Scientific Advisory Board with the appointment of Dr. Ken Takeshita, a renowned expert in biopharmaceuticals and clinical development. Dr. Takeshita has substantial experience leading global R&D initiatives and previously held senior positions at Kite Pharma and Celgene. His insights will significantly enhance I-Mab’s capabilities in immuno-oncology research.
I-Mab's Fulfilling Vision
As I-Mab navigates this new chapter, Mr. Wei Fu, the Chairman of the Board, expressed enthusiasm for how these appointments will elevate the Company’s trajectory. With a focus on the development of givastomig, the Company is poised to advance its pipeline of innovative therapies designed for treating various cancers, particularly gastric cancers.
About I-Mab
I-Mab (NASDAQ: IMAB) remains dedicated to pioneering advancements in precision immuno-oncology. Central to its mission is givastomig, a promising bispecific antibody targeting Claudin 18.2, which has shown remarkable potential during Phase 1 trials. Its unique mechanism of activating T cells within the tumor microenvironment positions givastomig for transformative potential in treating difficult-to-manage cancers, highlighting I-Mab's industrious approach in a competitive landscape.
Frequently Asked Questions
What is the main focus of I-Mab?
I-Mab is a global biotech company concentrated on developing precision immuno-oncology agents for cancer treatment.
Who are the new members of I-Mab's Board of Directors?
Dr. Robert Lenz and Ms. Xin Liu have been appointed as new independent directors, alongside Dr. Sean Cao, who continues his role.
What is the purpose of the new Research and Development Committee?
The R&D Committee aims to enhance I-Mab's innovation efforts and ensure strategic oversight of research initiatives.
What experience does Dr. Ken Takeshita bring to I-Mab?
Dr. Ken Takeshita is a distinguished biopharmaceutical executive with extensive experience in leading global research and clinical strategies.
How is I-Mab progressing with givastomig?
Givastomig has demonstrated strong tumor-binding and anti-tumor activities in early trials, indicating promising potential for future development.
